Molecular, clinical and prognostic characterization of double KRAS/PIK3CA (dKP) mutated metastatic colorectal cancer (mCRC)
نویسندگان
چکیده
منابع مشابه
Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications
The colorectal cancer (CRC) subtyping consortium has unified six independent molecular classification systems, based on gene expression data, into a single consensus system with four distinct groups, known as the consensus molecular subtypes (CMS); clinical implications are discussed in this review based on articles relevant to the CMS of CRC indexed in PubMed as well as the authors’ own ...
متن کاملFactors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)
Management of metastatic colorectal cancer requires a multimodal approach and must be performed by an experienced, multidisciplinary expert team. The optimal choice of the individual treatment modality, according to disease localization and extent, tumor biology, and patient clinical characteristics, will be one that can maintain quality of life and long-term survival, and even cure selected pa...
متن کاملRole of Molecular Biomarkers in Colorectal Cancer
Colorectal cancer (CRC) is amongst the most widespread cancers and is a most common cause of cancer associated mortality universally. Since previous decades, it has been cleared that CRC develops owing to the buildup of a series of genetic and epigenetic changes in the normal colonic epithelium. Regardless of the current development in surgery and therapies, overall survival of end stage CRC pa...
متن کاملVinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study
Background BRAF V600E mutation defines a specific colorectal cancer (CRC) subgroup with poor prognosis. Promising preclinical data showed synthetically lethal activity of mitotic spindle poisons on BRAF-mutated and BRAF-like CRC models. We designed a phase II trial to test the activity of vinorelbine in patients with BRAF V600E mutated metastatic CRC (mCRC). Patients and methods Patients prog...
متن کاملPrognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
BACKGROUND Bevacizumab (BEV) plus triplet chemotherapy can increase efficacy of first-line treatment of metastatic colorectal cancer (MCRC), particularly integrated with secondary liver surgery in liver-limited (L-L) patients. The prognostic value of the KRAS genotype in L-L and other or multiple metastatic (O/MM) MCRC patients treated with the FIr-B/FOx regimen was retrospectively evaluated. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2016
ISSN: 0923-7534
DOI: 10.1093/annonc/mdw370.108